Navigation Links
New hope for advanced post-menopausal breast cancer patients resistant to hormonal therapy
Date:9/25/2011

Stockholm, Sweden: Results from a phase III clinical trial have shown that combining two existing cancer drugs to treat post-menopausal women with advanced breast cancer resistant to hormonal therapy significantly improves outcome. Researchers told the 2011 European Multidisciplinary Cancer Congress [1] that women treated with a combination of everolimus and exemestane had an improved progression-free survival of nearly seven months compared to women who were treated only with exemestane.

Trial leader, Professor Jos Baselga from the Massachusetts General Hospital and Harvard Medical School, Boston (USA), will tell the meeting: "These results are impressive and, potentially, could represent a new therapeutic option for women with advanced post-menopausal breast cancer who have previously been treated with hormonal therapy."

The hormone oestrogen promotes the growth of about two thirds of breast cancers, and hormonal therapies such as exemestane, which block the effect of oestrogen or reduce oestrogen levels, are used to treat these hormone receptor-positive breast cancers. However, many breast cancer patients and nearly all patients with advanced breast cancer that has spread (metastasised) to other parts of the body become resistant to hormonal therapy. "When patients stop responding to hormonal therapy, the benefits from any secondary therapy are limited," says Prof. Baselga.

Exemestane is currently used to treat women who have metastatic breast cancer and women whose breast cancer has returned after initial treatment. It is also used to treat women with early breast cancer after they have completed two or three years of treatment with another hormonal therapy, tamoxifen.

Everolimus is an established treatment for recurrent, advanced kidney cancer and researchers are now looking at its use in other cancers. Phase II trials involving patients with advanced cancer driven by oestrogen receptor-positive advanced breast cancer have been promising when everolimus is used on its own or in combination with hormonal therapy. In order to follow this up, the phase III clinical trial BOLERO 2 was set up to investigate the efficacy of everolimus in patients who have become resistant to aromatase inhibitors drugs that decrease the amount of oestrogen produced and help to slow or reverse the growth of the cancer.

The multi-national trial was conducted with 724 patients in 24 countries, with an average age of 62. All patients had been treated previously with the aromatase inhibitors letrozole or anastrozole. Earlier treatments also included tamoxifen (48% of patients), fulvestrant (16% of patients) and chemotherapy (68% of patients).

A group of 485 patients was randomised to receive everolimus and exemestane, while 239 received only exemestane until the disease progressed or unacceptable levels of toxicity were recorded. The trial was stopped early after an interim analysis revealed that further tumour growth did not occur for nearly 11 months in patients who received everolimus, whereas patients receiving only exemestane had progression-free survival for approximately four months.

Prof Baselga says: "This is a highly significant improvement in the time to disease progression in a patient population that is highly resistant to therapy."

Trial sponsor Novartis plans to file worldwide regulatory submissions for everolimus as a treatment for oestrogen receptor-positive, advanced breast cancer by the end of 2011.


'/>"/>

Contact: Saffina Rana
saffina.rana@europe.com
ECCO-the European CanCer Organisation
Source:Eurekalert

Related medicine news :

1. Racial disparities persist in the diagnosis of advanced breast cancer and colon cancer in the U.S.
2. UH Case Medical Center researchers publish promising findings for advanced cervical cancer
3. Split-course palliative radiotherapy confirmed as effective treatment for advanced NSCLC
4. Drug for advanced kidney cancer shrinks tumors prior to surgery
5. Siemens Awards for Advanced Placement Honor Top U.S. Science and Math Students and Teachers
6. Family members reduce stress in advanced cancer patients with 14 minute massages
7. Accelerated radiation therapy reduces toxicity in patients with advanced head and neck cancers
8. Proton beam therapy shows encouraging long-term outcome for patients with locally advanced sinonasal cancers
9. Castrate-Metastatic Prostate Cancer: Therapeutic Considerations for Advanced Disease
10. AdvancedMD Appoints William Stone Vice President and General Manager of Billing Services Partner Program
11. BOTOX Cosmetic & Wrinkle Filler Specialist Hosts Advanced Training Event at Ageless Beauty in Mountain Home, ID
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... ... February 11, 2016 , ... PharmMD ... Counsel. Garrett will focus on contract negotiations, corporate strategy and healthcare data law. ... and best practices in data breaches for the Part D Star Rating improvement ...
(Date:2/11/2016)... ... February 11, 2016 , ... Greenfield Insurance Group in ... to assist the people of their local community. The agency pledges to select ... leaders. Their hope is to bring awareness to important local causes with fundraising ...
(Date:2/11/2016)... Island, NY (PRWEB) , ... February 11, 2016 ... ... has enhanced and updated its hallmark resource, Infusion Therapy Standards of Practice, to ... leader in vein illumination with an estimated 85% share of the market, facilitates ...
(Date:2/11/2016)... ... February 11, 2016 , ... Duterte ... community involvement program, introduces a new charity campaign to raise funds for Ronald ... being accepted at https://donate.rmhc.org/ . , Ronald McDonald House (RMH) is an ...
(Date:2/11/2016)... ... 2016 , ... The annual list showcases the 20 Most Promising SharePoint Solution ... dedication and commitment to the SharePoint ecosystem. A panel of experts and members of ... to recognize and promote technology entrepreneurship. , The survey was made at the ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... Fla. , Feb. 11, 2016 PLAD, ... started out 2016 with sales exceeding company targets, are ... have received their trademark from the United States Patent ... Bobby Clark , Chief Executive Officer of PLAD, Inc.  ... of Pennsylvania with two new ...
(Date:2/11/2016)... -- Community pharmacists can help improve medication adherence and patient ... custom-built medication synchronization program, Cardinal Health MedSync Advantage™. ... Schieber Family Pharmacy in Circleville, Ohio ... enrolled in this medication synchronization program, which is really ... patient, and it,s a win for us because it ...
(Date:2/11/2016)... 11, 2016  Delcath Systems, Inc. (NASDAQ: ... company focused on oncology with an emphasis on ... announces the engagement of Lars E. Birgerson ... Consultant. Dr. Birgerson will provide strategic medical advisory ... team to help ensure timely facilitation of new ...
Breaking Medicine Technology: